中国临床医学2017，Vol.24Issue(2)：253-256,4.DOI:10.12025/j.issn.1008-6358.2017.20160925
2001-2011年辽宁省三级医院适宜急性心肌梗死患者早期接受β受体阻滞剂的治疗趋势
Trend in early β-blocker use in patients with acute myocardial infarction in Class Ⅲ hospital in Liaoning Province from 2001 to 2011
摘要
Abstract
Objective:To assess the usage of β-blocker in patients with acute myocardial infarction (AMI) in early hospitalization period (admission within 24 hours) in Liaoning Province from 2001 to 2011.Methods:By convenience sampling, patients from 10 hospitals in 3 study years (2001, 2006, and 2011) were randomly selected and clinical data were extracted, the usage frequency, types and dosage of β-blocker were analyzed.Results:A total of 1 365 AMI patients from ten hospitals were included in this analysis, and about 296 cases (21.68%) were considered as ideal patients for early β-blocker use (53.10% cases in 2001, 68.70% cases in 2006, and 78% cases in 2011, P<0.001).Logistic regression analysis showed that the heart rate was related to the early usage of β-blocker.The most frequently used β-blocker was metoprolol (90.73%) within 3 years, only 1.46% had the dosage above 50 mg.Conclusions:During the past decade, the utilization rate of βB among the appropriate patients with AMI during the early-phase hospitalization in Liaoning Province present the increasing trend.However, there is a distinct gap between the utilization status and guideline.Although the early application can reduce the occurrence of cardiovascular event, the heart rate of patients and so on are the main causes that influence its application.Therefore, regarding the early application, it is necessary to comply with the evidence-based medical science and combine it with the individualization principle.关键词
β受体阻滞剂/急性心肌梗死/适宜人群/趋势/患者特征Key words
β-blockers/acutmyocardial infarction/ideal patients/trend/patient characteristics分类
医药卫生引用本文复制引用
陈丽波,于勤,李晓菲,那荣妹,尹力,涂文程,李竹,孟莉莉,李倩晓,刘百亭..2001-2011年辽宁省三级医院适宜急性心肌梗死患者早期接受β受体阻滞剂的治疗趋势[J].中国临床医学,2017,24(2):253-256,4.基金项目
卫生公益性行业科研专项基金(201202025).Supported by Special Fund for Scientific Research in the Public Health Industry(201202025). （201202025）
